HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takashi Kadowaki Selected Research

Metabolic Diseases (Metabolic Disease)

11/2017Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering.
1/2015Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians.
9/20085-Hydroxytryptamine 2A receptor signaling cascade modulates adiponectin and plasminogen activator inhibitor 1 expression in adipose tissue.
4/2005[PPAR and diabetes].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takashi Kadowaki Research Topics

Disease

121Type 2 Diabetes Mellitus (MODY)
10/2022 - 01/2002
113Insulin Resistance
11/2021 - 01/2002
67Obesity
01/2022 - 01/2002
37Atherosclerosis
01/2022 - 07/2002
37Body Weight (Weight, Body)
01/2022 - 02/2002
26Glucose Intolerance
01/2022 - 07/2002
26Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2021 - 10/2003
24Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 01/2005
20Hypoglycemia (Reactive Hypoglycemia)
04/2021 - 12/2004
20Diabetes Mellitus
06/2020 - 01/2002
18Hyperglycemia
01/2020 - 01/2002
17Neoplasms (Cancer)
01/2022 - 01/2003
15Inflammation (Inflammations)
01/2022 - 08/2002
15Hypertension (High Blood Pressure)
12/2021 - 11/2002
13Hypertrophy
06/2015 - 01/2002
9Carcinogenesis
01/2017 - 02/2003
8Diabetes Complications
12/2021 - 02/2004
7Coronary Artery Disease (Coronary Atherosclerosis)
10/2020 - 04/2005
6Type 1 Diabetes Mellitus (Autoimmune Diabetes)
04/2021 - 01/2010
6Stroke (Strokes)
01/2021 - 08/2004
6Adult-onset citrullinemia type 2
12/2019 - 08/2007
5Hypoadiponectinemia
09/2022 - 09/2002
5Chronic Renal Insufficiency
01/2022 - 06/2018
5Myocardial Infarction
12/2021 - 12/2017
5Ischemia
12/2021 - 06/2003
5Albuminuria
08/2021 - 10/2007
5Fibrosis (Cirrhosis)
02/2020 - 03/2005
5Weight Gain
06/2019 - 02/2010
5Hypercholesterolemia
01/2016 - 07/2004
5Fatty Liver
07/2012 - 05/2004
4Weight Loss (Weight Reduction)
01/2019 - 07/2004
4Hyperinsulinism (Hyperinsulinemia)
11/2018 - 06/2004
4Metabolic Diseases (Metabolic Disease)
11/2017 - 04/2005
3Drug-Related Side Effects and Adverse Reactions
10/2022 - 11/2013

Drug/Important Bio-Agent (IBA)

71Glucose (Dextrose)FDA LinkGeneric
01/2022 - 02/2002
63Insulin (Novolin)FDA Link
12/2021 - 01/2002
62AdiponectinIBA
09/2022 - 02/2002
30PPAR gammaIBA
02/2010 - 01/2002
24Triglycerides (Triacylglycerol)IBA
12/2021 - 02/2005
22Hypoglycemic Agents (Hypoglycemics)IBA
11/2020 - 12/2003
18LipidsIBA
01/2021 - 01/2003
17Blood Glucose (Blood Sugar)IBA
12/2021 - 04/2003
15Proteins (Proteins, Gene)FDA Link
02/2020 - 08/2002
14Insulin ReceptorIBA
11/2021 - 06/2003
14CholesterolIBA
01/2020 - 07/2004
133- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA
01/2022 - 11/2013
13Insulin Receptor Substrate ProteinsIBA
12/2018 - 11/2002
12AdipokinesIBA
09/2022 - 02/2004
12Pharmaceutical PreparationsIBA
01/2021 - 02/2005
12LigandsIBA
01/2016 - 03/2002
11LeptinIBA
09/2022 - 09/2002
11Fatty Acids (Saturated Fatty Acids)IBA
12/2021 - 01/2003
11Messenger RNA (mRNA)IBA
12/2018 - 12/2003
11Adiponectin ReceptorsIBA
01/2017 - 12/2003
10EnzymesIBA
12/2021 - 06/2004
10Insulin Glargine (Lantus)FDA Link
03/2017 - 06/2009
10Pioglitazone (Actos)FDA Link
11/2013 - 03/2002
9SodiumIBA
01/2022 - 08/2005
8Transcription Factors (Transcription Factor)IBA
01/2020 - 03/2003
8Hemoglobins (Hemoglobin)IBA
04/2016 - 04/2007
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2016 - 09/2002
8CytokinesIBA
12/2013 - 09/2002
7Sodium-Glucose Transporter 2 InhibitorsIBA
01/2022 - 12/2015
7HDL CholesterolIBA
12/2021 - 05/2007
7LDL CholesterolIBA
01/2021 - 11/2008
7Sitagliptin Phosphate (Januvia)FDA Link
01/2021 - 10/2011
7Hormones (Hormone)IBA
09/2014 - 07/2002
7Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
05/2011 - 07/2002
7Rosiglitazone (Avandia)FDA Link
10/2009 - 07/2002
6citrinIBA
12/2019 - 08/2007
6Peroxisome Proliferator-Activated Receptors (PPAR)IBA
06/2015 - 04/2005
6CalciumIBA
09/2014 - 12/2004
6Antihypertensive Agents (Antihypertensives)IBA
05/2007 - 08/2005
5Apolipoproteins E (ApoE)IBA
01/2022 - 01/2003
5Biological ProductsIBA
11/2017 - 02/2003
5C-Reactive ProteinIBA
01/2016 - 08/2009
52,4-thiazolidinedione (thiazolidinedione)IBA
06/2011 - 03/2006
5AMP-Activated Protein KinasesIBA
06/2011 - 03/2006
4LinagliptinIBA
10/2022 - 01/2020
4Sodium-Glucose Transport ProteinsIBA
01/2022 - 01/2017
4CanagliflozinIBA
01/2022 - 01/2017
4empagliflozinIBA
01/2022 - 06/2014
4Dipeptidyl-Peptidase IV InhibitorsIBA
01/2022 - 07/2013
4insulin degludecIBA
04/2021 - 09/2016
4AdipoRonIBA
01/2021 - 11/2013
4glimepiride (Amarel)FDA LinkGeneric
01/2021 - 12/2008
4CarbohydratesIBA
12/2019 - 11/2012
4Sterol Regulatory Element Binding Protein 1IBA
01/2019 - 06/2005
4GlucokinaseIBA
12/2018 - 06/2004
4Peptides (Polypeptides)IBA
10/2017 - 02/2002
4C-PeptideIBA
01/2017 - 01/2010
4Glycerolphosphate Dehydrogenase (Glycerol 3 Phosphate Dehydrogenase)IBA
09/2015 - 08/2007
4oxidized low density lipoproteinIBA
07/2013 - 09/2006
4Pyruvic Acid (Pyruvate)IBA
11/2012 - 08/2007
4ThiazolidinedionesIBA
05/2011 - 04/2005
4PPAR alphaIBA
12/2005 - 12/2003

Therapy/Procedure

39Therapeutics
09/2022 - 08/2002
22Glycemic Control
08/2021 - 04/2007
6Drug Therapy (Chemotherapy)
01/2022 - 11/2008
4Injections
01/2016 - 06/2010